Albany Molecular Research (AMRI) – Company Press Releases
-
First Patient Dosed in the ENLIGHTEN Biomarker-Guided Global Clinical Trial of DB104 (Liafensine) for Treatment-Resistant Depression
-
Nemus Bioscience, Inc. Signs Agreement with Albany Molecular Research Inc. (AMRI) to Manufacture Cannabinoid-Based Active Pharmaceutical Ingredient for Glaucoma
-
3ST Research Files Litigation Alleging Fraud and Conversion of Inventor's Intellectual Property Rights by Albany Molecular Research Inc. (AMRI)
-
AMRI Announces Completion of Acquisition by The Carlyle Group and GTCR
-
Control4 Set to Join S&P SmallCap 600
-
AMRI Announces Early Termination of HSR Waiting Period for The Carlyle Group and GTCR's Proposed Acquisition of AMRI
-
AMRI Signs Definitive Agreement To Be Acquired By The Carlyle Group and GTCR for $21.75 per share in cash
-
AMRI to Present at Jefferies Healthcare Conference
-
AMRI Announces First Quarter 2017 Results
-
AMRI Receives NIH Contract Award for Drug Substance Development and Manufacturing Services
-
SSCI Receives a 2017 Biotechnology Award for Global Research and Manufacturing
-
AMRI Schedules First Quarter 2017 Earnings Release and Conference Call
-
Denovo Biopharma Obtains Exclusive License To Liafensine From AMRI
-
AMRI Receives CMO Leadership Awards for Excellence
-
AMRI to Present at Barclays Global Healthcare Conference
-
AMRI Announces Agreement with Accord Healthcare to Jointly Develop, Manufacture and Commercialize Parenteral Drug Products
-
AMRI Announces Fourth Quarter and Full Year 2016 Results and Provides 2017 Outlook
-
AMRI Schedules Fourth Quarter and Full Year 2016 Earnings Release and Conference Call
-
AMRI Announces Strategic Alliance to Advance Mass Spectrometry Capabilities for Drug Discovery
-
AMRI CEO to Present at 35th Annual J.P. Morgan Healthcare Conference
-
AMRI Announces API Supply Agreement with Shire
-
AMRI to Present Two Posters at AAPS 2016
-
AMRI Announces Third Quarter 2016 Results
-
AMRI Schedules Third Quarter 2016 Earnings Release and Conference Call
-
AMRI to Unveil Powerful Portfolio of APIs and Capabilities at CPhI in Barcelona
-
AMRI CEO to Present at Morgan Stanley Global Healthcare Conference
-
AMRI CEO to Present at Morgan Stanley Global Healthcare Conference
-
AMRI CEO to Present at Baird 2016 Global Healthcare Conference
-
AMRI Licenses CRISPR-Cas9 Gene Editing Technology
-
AMRI Announces Second Quarter 2016 Results
-
AMRI to Announce Second Quarter 2016 Results
-
AMRI Completes Acquisition of Euticals
-
Teewinot Life Sciences Corporation Licenses Biosynthetic Technology to AMRI for the Production and Sale of the First Commercially Available CBCA Analytical Standard
-
AMRI Selected as a Dedicated Chemical Biology Consortium Center to Expand Drug Development
-
AMRI CEO to Present at Jefferies 2016 Healthcare Conference
-
AMRI Clarifies 2016 Revenue Guidance
-
AMRI Announces First Quarter 2016 Results
-
AMRI Appoints Louis Yu, Ph.D., as Senior Vice President, Quality and Compliance
-
AMRI to Acquire Euticals in a Strategic Transaction That Expands its API Development and Manufacturing Business
-
AMRI to Announce First Quarter 2016 Results
-
AMRI Announces Filing of Annual Report on Form 10K
-
AMRI Wins Four Life Science Leader Awards
-
AMRI Announces Extension to File Form 10K for 2015
-
AMRI Announces Fourth Quarter and Full Year 2015 Results and Provides 2016 Outlook
-
AMRI Appoints David H. Deming and Kenneth P. Hagen to Board of Directors
-
AMRI to Announce Fourth Quarter and Full Year 2015 Results
-
NEMUS Bioscience, Inc. Signs Agreement With Albany Molecular Research Inc. (AMRI) to Manufacture Cannabinoid-Based Active Pharmaceutical Ingredients
-
AMRI Appoints Anthony J. Maddaluna to Board of Directors
-
AMRI Announces Executive Hire to Lead Active Pharmaceutical Ingredients Business
-
AMRI and NYCNMR Form Collaborative Agreement
Back to AMRI Stock Lookup
